Therapy with anti-mIL-6R/sIL-6R mAbs (e.g., tocilizumab and sarilumab) may help to suppress the cytokine storm in severe cases of COVID-19 [118,119]; however, the consistent message of related studies is that there is no broad-based benefit of IL-6 blockade in COVID-19 patients. This evidence concerns the gene IL6R and COVID-19.